Production (Stage)
United Therapeutics Corporation
UTHR
$295.52
-$4.64-1.55%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 15.25% | 21.35% | 23.46% | 22.71% | 44.24% |
| Total Depreciation and Amortization | 40.80% | 36.28% | 26.19% | 16.06% | 5.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 145.04% | 216.67% | 10.32% | -1.20% | -68.70% |
| Change in Net Operating Assets | 88.12% | 38.45% | -57.29% | 22.08% | -126.13% |
| Cash from Operations | 44.11% | 35.70% | 18.95% | 27.39% | 10.25% |
| Capital Expenditure | -24.59% | -6.99% | -24.74% | -17.19% | -36.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -136.07% | 265.93% | 219.79% | 230.45% | 209.18% |
| Cash from Investing | -303.89% | 157.98% | 161.25% | 152.49% | 135.16% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -100.00% | -300.00% | -- | -- | -- |
| Issuance of Common Stock | 57.74% | 53.06% | -7.20% | -25.61% | -43.30% |
| Repurchase of Common Stock | 98.41% | -7,234.78% | -7,286.86% | -7,231.88% | -7,231.16% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash from Financing | 75.14% | -10,444.54% | -1,033.21% | -984.54% | -935.93% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 636.82% | 98.58% | 216.68% | 5.99% | -74.87% |